登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688382 证券简称：益方生物 公告编号：2026-006 益方生物科技（上海）股份有限公司 第二届董事会2026年第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 益方生物科技（上海）股份有限公司（以下简称"公司"）第二届董事会2026年第一次会议（以下简 称"本次会议"）于2026年2月10日在公司会议室以现场及通讯表决方式召开，本次会议通知已于2026年2 月5日通过书面方式送达全体董事。本次会议由董事长Yaolin Wang（王耀林）先生召集并主持，会议应 出席董事9人，实际出席董事9人，公司高级管理人员列席本次会议。本次会议的召集、召开和表决程序 符合《中华人民共和国公司法》等法律法规和《益方生物科技（上海）股份有限公司章程》的规定，会 议决议合法、有效。 二、董事会会议审议情况 出席会议的董事审议通过以下议案： （一）审议通过《关于调整部分募集资金投资项目内部投资结构的议案》 同意公司调整募投项目"新药研发项 ...

中访网数据 益方生物科技（上海）股份有限公司于2026年2月10日召开董事会，审议通过了调整部分募 集资金投资项目内部投资结构的议案。核心决策为：在募集资金总额不变的前提下，对"新药研发项 目"的内部投资结构进行优化。具体调整包括新增临床前候选药物"YF550"作为子项目，并重新分配各 子项目资金。关键数据方面，公司将向口服TYK2抑制剂D-2570项目追加投入23,210.95万元，用于推进 其在银屑病、溃疡性结肠炎等多个自身免疫性疾病领域的临床试验；同时，为临床前项目YF087、 YF550及探索性研究分别新增投入4,720万元、4,290万元和2,000万元。相应地，用于URAT1抑制剂D- 0120项目的募集资金将调减34,220.95万元。此次调整旨在将资源更集中于研发进展较快、市场潜力较大 的核心管线，以提升资金使用效率，加速产品开发进程。该议案尚需提交公司股东大会审议批准。公司 提示，创新药研发存在临床试验结果不及预期、市场竞争及商业化不确定性等风险。 ...

智通财经APP获悉，中国证监会发布《境外发行上市备案补充材料要求(2026年2月2日—2026年2月6 日)》。中国证监会国际司共对4家企业出具补充材料要求，其中，要求益方生物补充说明安全生产等方 面的合规运作情况等事项。据港交所1月1日披露，益方生物(688382.SH)向港交所主板递交上市申请， 中信证券为其独家保荐人。 中国证监会请益方生物补充说明以下事项，请律师核查并出具明确的法律意见： 截至2025年12月24日，公司已建立了全面且差异化的产品管线，包括两款商业化产品(贝福替尼(BPI- D0316)及格索雷塞(D 1553))、两款临床阶段核心产品(D-2570及泰瑞司群(D-0502))、一款临床阶段候选 产品(达比诺雷(D-0120))及三个临床前候选产品(YF087、YF550及YF057)。 招股书显示，益方生物是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫 性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。 一、发行人下属公司经营范围涉及"设计、制作、代理、发布各类广告"。请说明发行人及下属公司的经 营范围及实际业务经营是否涉及禁止、限制外商投资的领域及相关 ...

Group 1 - The core viewpoint of the news is that Yifang Biotechnology (Shanghai) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - Yifang Biotechnology is a research-driven biopharmaceutical company based in China, focusing on significant diseases with unmet needs, including oncology, autoimmune diseases, and metabolic diseases [1] - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, which includes two commercialized products (BPI-D0316 and D 1553), two core products in clinical stages (D-2570 and D-0502), one clinical candidate (D-0120), and three preclinical candidates (YF087, YF550, and YF057) [1]

Group 1 - Longhang Asset recently conducted research on Yifang Bio, highlighting the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - The drug Gesorex (brand name Anfangning) received approval from the National Medical Products Administration for the treatment of advanced non-small cell lung cancer (NSCLC) in adults with KRS G12C mutations, with multiple clinical studies ongoing [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1] Group 2 - Longhang Asset Management Company is a professional asset management firm based in Shanghai, with a core team possessing 18 years of industry investment experience [2] - The company adheres to a value investment philosophy, utilizing various financial tools to manage client assets for sustainable growth [2] - Longhang Asset emphasizes research-driven investment and the importance of a rigorous scientific investment process [2]

Group 1 - Qianyi Investment recently conducted research on Yifang Biotechnology, highlighting the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - Gexuolei Tablets (brand name Anfangning) received approval from the National Medical Products Administration for market launch in November 2024, targeting adult patients with advanced non-small cell lung cancer harboring KRS G12C mutations who have undergone at least one systemic treatment [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1]

Group 1 - Xin Yuan Fund recently conducted research on a listed company, Yifang Bio, discussing the latest progress of multiple drugs under development [1] - Drug D-2570 is planned for clinical exploration in various autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - The drug Gesorex (brand name Anfangning) is expected to be approved by the National Medical Products Administration for advanced non-small cell lung cancer (NSCLC) patients with KRS G12C mutation by November 2024, with multiple clinical studies ongoing [1] - Drug D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - Drug D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1] Group 2 - Xin Yuan Fund was established in 2013, with a total asset management scale of 212.33 billion yuan, ranking 35th out of 210 [2] - The asset management scale for non-monetary public funds is 140.64 billion yuan, also ranking 35th out of 210 [2] - The fund manages 162 public funds, ranking 47th out of 210, with 22 public fund managers, ranking 63rd out of 210 [2] - The best-performing public fund product in the past year is Xin Yuan Guozheng 2000 Index Enhanced A, with a latest net value of 1.23 and a growth of 60.06% over the past year [2] - The latest public fund product raised by Xin Yuan is Xin Yuan Science and Technology AI Index Initiated A, with a subscription period from July 25, 2025, to August 8, 2025 [2]

Core Viewpoint - The company is committed to enhancing operational efficiency and management quality through its 2025 "Quality Improvement and Efficiency Enhancement" action plan, focusing on innovation in drug development and protecting the rights of investors, especially small and medium-sized investors [1][12]. Group 1: Business Strategy and Development - The company aims to accelerate the layout of its core pipeline, focusing on major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to developing innovative drugs with independent intellectual property rights [1][2]. - The company has two authorized products on the market, one in the registration clinical trial stage, two in Phase II clinical trials, and multiple preclinical projects, indicating a strong position in research and development [2]. - The company plans to advance the clinical research of its D-2570 product, which has shown promising results in Phase II trials for psoriasis, and will explore its potential in other autoimmune diseases [2][3]. Group 2: Research and Development Capabilities - The company has established a comprehensive R&D system that enhances the success rate of its products and shortens drug development cycles through precise target selection and clinical development processes [2][4]. - The company has a core R&D team with over 20 years of experience in multinational pharmaceutical companies, which strengthens its capabilities in drug design and clinical trial execution [4][5]. - The company has applied for 370 domestic and international invention patents, with 129 granted, ensuring the commercial value of its innovations and reducing potential patent infringement risks [6]. Group 3: Team and Talent Management - The R&D team constitutes over 90% of the company's workforce, with leaders possessing extensive industry experience, which is crucial for the drug development process [7]. - The company plans to implement a new round of equity incentive plans to attract and retain talent, aligning the interests of shareholders and the core team [7]. Group 4: Financial Management and Fund Utilization - The company is focused on improving the efficiency of its fundraising projects and has made adjustments to its headquarters construction project to better meet R&D needs [8]. - In 2025, the company will increase investment in new drug R&D projects, aiming to enhance the efficiency of clinical trials and expand its clinical pipeline [8]. Group 5: Corporate Governance and Compliance - The company is revising its governance structure, including the cancellation of the supervisory board and the enhancement of the board's responsibilities to improve oversight and protect investor rights [9][17]. - The company emphasizes the importance of internal controls and compliance with relevant laws and regulations to ensure effective management of significant matters [9]. Group 6: Information Disclosure and Investor Relations - The company is committed to enhancing the quality of information disclosure and actively engages with investors through various communication channels [10][11]. - The company plans to conduct at least three performance briefings annually to maintain transparency and keep investors informed about its operations and financial status [11].